RX Biosyent Inc

BioSyent Inc. (TSX VENTURE:RX) ("BioSyent") is pleased to announce that its
subsidiary, BioSyent Pharma Inc., has submitted two new drug products to Health
Canada seeking marketing approval.


These two urgent care drugs are supplied in a patented delivery system that
offers technical advantages over existing alternatives and will be used in
hospitals and acute care settings. These products will provide hospitals,
clinics, and healthcare professionals with improved patient safety as well as
operational efficiencies and will complement BioSyent's Hospital Division.


"These two products are consistent with our strategy of sourcing unique and
innovative pharmaceutical products for the Canadian market," said Rene Goehrum,
President and CEO of BioSyent. "There are additional products under development
by our European partner and we look forward to exploring additional product
candidates utilizing the same patented technology. Due diligence on the next
product has already commenced."


The products will be launched after Health Canada grants marketing approval.

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and
other Company financial information please visit www.tmxmoney.com.


About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent
is a profitable growth oriented specialty pharmaceutical company which searches
the globe to in-license or acquire innovative pharmaceutical products that have
been successfully developed, are safe and effective, and have a proven track
record of improving the lives of patients and supporting the healthcare
professionals that treat them.


Once a product of interest has been found, BioSyent then acquires the exclusive
rights to the product and manages it through the Canadian governmental
regulatory approval process. Once approved, BioSyent markets the product
throughout Canada.


At the date of this press release the Company had 13,571,195 shares issued and
outstanding.


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.


FOR FURTHER INFORMATION PLEASE CONTACT: 
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
(905) 206-0013
investors@biosyent.com
www.biosyent.com

Biosyent (TSXV:RX)
Historical Stock Chart
From Mar 2024 to Apr 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Apr 2023 to Apr 2024